SOCS3 and myeloproliferative disorder: Histone deacetylase inhibitor, that is, sodium butyrate, increases the transcript and protein expression levels of SOCS1 and SOCS3 by triggering the histone acetylation of SOCS1 and SOCS3 gene promoters in myeloproliferative neoplasm (84).